IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/523639

Rec'd PCT/PTO 0 4 FEB 2005

In re Patent Application of											
GAR	NIER et	al	Atty. Ref.:	620-360							
Seria	l No.: Ur	nassigned	Group:	Unassigned							
U.S.	National	Phase of PCT/EP2003/008928	Examiner:	Unassigned							
Filed	ed: February 4, 2005										
For:	For: PRODUCTION OF MULTIMERIC FUSION PROTEINS USING A C4BP SCAFFOLD										
		* * * * * * *	* * * *								
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450											
Sir: INFORMATION DISCLOSURE STATEMENT											
	1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits] N/C									
	2.(a)	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance Statement or Rule 17(p) fee)]		ıle 97(e) N/C							
	2 .(b)	Fee Payment Pursuant to 37 CFR 1.9 [before Final Office Action or Allowance Statement or Rule 17(p) fee)]	• •	ule 97(e) <i>\$180.00</i>							

[after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]

Statement or Rule 17(p) fee)]

Pursuant to 37 CFR 1.97(d)

3.

\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

⊠ 4		A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. A copy of the International Search Report issued in connection with PCT/EP2003/008928 and copies of the cited references are attached.					
This pap	oer is	sub	mitted in accordance with:				
⊠ 5	j.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]					
<u> </u>	S.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier] and					
		a)	The required Statement made in item 8 below; or				
		b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.				
□ 7	' .	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and					
. [a)	The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and				
		b)	The required Statement is stated in item 8 below.				
□ 8	3.	Statement under 37 CFR 1.97(e)					
]	a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or				
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information				

GARNIER et al Serial No. Unassigne U.S. National Phase of PCT/EP2003/008928

2 Rec'd PCT/PTO -0 4 FEB 2005

contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

Ву:

B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000

Facsimile: (703) 816-4100

Sheet 1 of 1



10/523639 2 Rec'd POWETO 0 4 FEB 2005 SERIAL NO.

INFORMATION DISCLOSURE ATTY, DOCKET NO.

	CITATION	620-3		371 of PCT/EP2003/008928 Unassigned				
			APPLICANT					
(1100	several sheets if necessary)	GARI	GARNIER et al					
(OSE	several sheets if necessary)			GROUP Unassigned				
			uary 4, 2005 S. PATENT DOCUMENTS	Orlassigned				
*EXAMINER							DATE	
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPRO	OPRIATE_	
			-					
								
						<u> </u>		
						-		
							·	
		FORI	EIGN PATENT DOCUMENT	<u>'S</u>		TRANS	LATION	
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
	WO 91/11461	08/1991	WIPO			ļ		
	WO 97/04109	02/1997	WIPO					
		<u> </u>						
		<u> </u>						
					_ ,			
			cluding Author, Title, Date,)		
			er 15, 1997, Vol. 90, No. 10,			1505.1	540	
<u> </u>			mmunology, February 1, 200				513	
	Christiansen et al, Journal of Virology, May 2000, Vol. 74, No. 10, pp 4672-4678 Shinya et al, Biomedicine & Pharmacotherapy, December 1999, Vol. 53, No. 10, pp 471-							
	483	euicine &	глаппасошегару, ресеть	ы тэээ, VUI.; 	JS, INU. II	, pp 4	<i>,</i> 1-	
	Blom et al, Biochi	mica et Bio	ophysica Acta, October 14, 1	998, Vol. 138	8, No. 1,	pp 181	l-189	
*Examiner			Date Considered					
	I if reference considered, whether with next communication to applic		conformance with MPEP 609; Draw line through					
					Form PTO-FB-	A820 (Also	PTO-1449	

922923